While Amgen Sees Success For Two Growth Drivers, Headwinds Remain
Breakthrough Drugs Sotorasib, Tezepelumab Edge Closer To Market
Scrip discussed key wins for sotorasib in lung cancer and tezepelumab in asthma with Amgen executives Murdo Gordon and David Reese, but COVID-19 and other challenges are looming.
